Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Daniel Ebner

Group Head / PI and Member of congregation

Daniel Ebner is an Associate Professor and Principal Investigator at the University of Oxford and heads the TDI High Throughput Cellular Screening Facility and the Oxford CRISPR/Cas9 Screening Facility at the Target Discovery Institute (TDI), Centre for Medicines Discovery, Nuffield Department of Medicine. Daniel’s main academic research, through a five year £7M CRUK funded grant in collaboration with researchers from the University of Edinburgh and MIT, is focused on identifying and advancing novel combinatorial therapeutics for the treatment of glioblastoma. As head of the cellular screening facility, Daniel has worked with academic and industrial collaborators to complete >150 research projects and has published >70 peer-reviewed papers in the past 5 years in high impact  journals such as the Lancet, New England Journal of Medicine, Nature and Journal of the American Medical Association across a broad range of pathologies including on neurodegeneration, inflammation, autophagy, large-scale iPSC CRISPR/Cas9 screening methods, and novel more physiologically relevant screening models. Previous to his academic career at the University of Oxford, Daniel has worked for >10 years in the biotechnology and pharmaceutical industry.